Lobenzarit

Lobenzarit

SCHEMBL1479150

O=C(O)c1ccccc1Nc1cc(Cl)ccc1C(=O)O.[NaH]

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 10/20 0.61
AKR1C3 P42330 2/20 0.60
AKR1B10 O60218 1/20 0.60
AKR1B1 P15121 1/20 0.60
AKR1C4 P17516 1/20 0.60
AKR1C2 P52895 1/20 0.60
AKR1C1 Q04828 1/20 0.60
FTO Q9C0B1 2/20 0.58
PBRM1 Q86U86 1/20 0.58
FABP4 P15090 4/20 0.57
TTR P02766 2/20 0.56
MEN1 O00255 1/20 0.56
USP2 O75604 1/20 0.56
MT-CO2 P00403 1/20 0.56
LMNA P02545 1/20 0.56
PLA2G1B P04054 1/20 0.56
CYP1A2 P05177 1/20 0.56
PGR P06401 1/20 0.56
CYP3A4 P08684 1/20 0.56
HTR1A P08908 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lobenzarit SCHEMBL7935 1.00 GRIK1 (0.61) GRIK1AKR1C3AKR1B10AKR1B1AKR1C4
Lobenzarit SCHEMBL187951 0.98 GRIK1 (0.63) GRIK1AKR1C3AKR1B10AKR1B1AKR1C4
Lobenzarit SCHEMBL30753983 0.98 GRIK1 (0.63) GRIK1AKR1C3AKR1B10AKR1B1AKR1C4
Lobenzarit SCHEMBL9621335 0.97 GRIK1 (0.61) GRIK1AKR1C3AKR1B10AKR1B1AKR1C4
Lobenzarit SCHEMBL29453054 0.97 GRIK1 (0.61) GRIK1AKR1C3AKR1B10AKR1B1AKR1C4
SCHEMBL6140792 0.90 FABP4 (0.62) GRIK1AKR1C3AKR1B10AKR1B1AKR1C4
SCHEMBL11603313 0.89 GRIK1 (0.62) GRIK1AKR1C3AKR1C2MEN1USP2
SCHEMBL14576292 0.89 GRIK1 (0.73) GRIK1AKR1C3FTOPBRM1FABP4
SCHEMBL30611313 0.89 GRIK1 (0.73) GRIK1AKR1C3FTOPBRM1FABP4
SCHEMBL16489012 0.89 EGFR (0.66) GRIK1AKR1C3AKR1B10AKR1C2AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9023889-B2 Use of ascorbic acid derivatives for the functionalization of matrices MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-7914893-B2 Particles comprising an anion-binding layer containing anion-forming organic active compounds, and method of making and using thereof MERCK PATENT GMBH (DE) 2011-03-29 US disclosed
US-20100167936-A1 USE OF ASCORBIC ACID DERIVATIVES FOR THE FUNCTIONALIZATION OF MATRICES MERCK PATENT GESELLSCHAFT (DE) 2010-07-01 US disclosed
US-20070275244-A1 Particles MERCK PATENT GMBH 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100167936-A1 USE OF ASCORBIC ACID DERIVATIVES FOR THE FUNCTIONALIZATION OF MATRICES PROC, TTPA, COX6C GRIK1 3423/4885AKR1C3 339/4885AKR1B10 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.